Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.
We assessed the risk of clinically significant drug interactions in patients receiving antiretrovirals, and their recognition by physicians. Clinically significant drug interactions were recorded in 27% of 159 patients, with 15% of interactions potentially lowering antiretroviral concentrations. Risk of clinically significant drug interactions was significantly related to receipt of protease inhibitors. Only 36% of clinically significant drug interactions were correctly identified by physicians.
Evans-Jones
John G
JG
Department of Genitourinary Medicine, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
Cottle
Lucy E
LE
Back
David J
DJ
Gibbons
Sara
S
Beeching
Nicholas J
NJ
Carey
Peter B
PB
Khoo
Saye H
SH
D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006302:Health Services Research; D006801:Humans; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment; D055815:Young Adult
D019380:Anti-HIV Agents